Today’s interims are in line with management’s expectations with losses before tax in the period of £15.7m (vs. £14.1m prior year). Cash was reported to be £10.0m, which after accounting for the post period-end £7.7m (gross) fundraising provides sufficient cash runway into Q1 2021 and through multiple key milestones across the pipeline. Whilst Covid-19 has impacted the timeline of data for two trials (asthma and pancreatic cancer), in the coming weeks we eagerly await full Phase II topline resul ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In line interims; IBS Phase II data imminent
- Published:
30 Sep 2020 -
Author:
Edward Thomason -
Pages:
3
Today’s interims are in line with management’s expectations with losses before tax in the period of £15.7m (vs. £14.1m prior year). Cash was reported to be £10.0m, which after accounting for the post period-end £7.7m (gross) fundraising provides sufficient cash runway into Q1 2021 and through multiple key milestones across the pipeline. Whilst Covid-19 has impacted the timeline of data for two trials (asthma and pancreatic cancer), in the coming weeks we eagerly await full Phase II topline resul ....